Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...

SARCLISA binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. CD38 is highly and uniformly expressed on the surface of MM cells ...

对于中国MM患者来说，西达基奥仑赛的获批 ... 使用标准疗法（包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体）治疗后复发的患者会面临预后 ...

South San Franciso, California Friday, September 6, 2024, 16:30 Hrs [IST] ...

多发性骨髓瘤被认为是不可治愈的血液肿瘤，是由于骨髓中的浆细胞过度增殖导致的恶性疾病。据美国癌症协会估计，2022年美国将有超过34000人被诊断为多发性骨髓瘤，超过12000人因此死亡。虽然有些多发性骨髓瘤患者无明显症状，但大多数患者是由于出现症状而 ...

在世界剧场之上，biotech这个行业里有着更多的诱惑，有着更为血淋的失败，一轮宏观周期砸死一片双创公司，也有不少倒下后的重新崛起。这里有着 ...

NEW YORK, NY, USA I 11, 2024 I Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage ...

过去十多来，孤儿药的增长速度超过了非孤儿处方药，在全球处方药销售额中所占的份额翻了一番，从2014年的不到10%增至如今的近20%。预计孤儿药2024年的全球销售额将达到1850亿美元，到2028年将接近2700亿美元。

MM continues to be a therapeutically challenging ... but not limited to, mAbs specific for CD38, CS1, CD40, CD74, CD70, HM1.24, IL-6 and B2MG directed against a number of potential targets for ...

Clinical studies of rituximab therapy for MM have been disappointing, as only a few of the patients showed minimal response. [7] The failure of rituximab in this setting is potentially ...